| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|---|
Gross Sales | 16,629.91 | 14,761.23 | 11,939.68 | 12,328.29 | 11,167.72 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 16,629.91 | 14,761.23 | 11,939.68 | 12,328.29 | 11,167.72 |
Other Operating Income | 410.86 | 288.8 | 271.9 | 194.16 | 212.5 |
Other Income | 138.87 | 90.92 | 36.09 | 127.05 | 90.19 |
Total Income | 17,179.64 | 15,140.95 | 12,247.67 | 12,649.5 | 11,470.41 |
Total Expenditure | 13,078.63 | 12,236.36 | 10,991.23 | 12,503.89 | 9,531.85 |
PBIDT | 4,101.01 | 2,904.59 | 1,256.44 | 145.61 | 1,938.56 |
Interest | 205.77 | 240.32 | 181.75 | 101.3 | 108.8 |
PBDT | 3,895.24 | 2,664.27 | 1,074.69 | 44.31 | 1,829.76 |
Depreciation | 776.08 | 739.71 | 616.7 | 1,331.52 | 671.69 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 709.58 | 527.81 | 216.77 | 74.94 | 417.82 |
Deferred Tax | -114.3 | -170.6 | 35.92 | -364.52 | -23.31 |
Reported Profit After Tax | 2,523.88 | 1,567.35 | 205.3 | -997.63 | 763.56 |
Minority Interest After NP | 14.78 | 12.3 | 11.18 | 12.43 | 7.39 |
Net Profit after Minority Interest | 2,509.1 | 1,555.05 | 194.12 | -1,010.06 | 756.17 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 2,509.1 | 1,555.05 | 194.12 | -1,010.06 | 756.17 |
EPS (Unit Curr.) | 55.02 | 34.17 | 4.27 | -22.25 | 16.69 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 91.25 | 91.07 | 90.96 | 90.84 | 90.7 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 24.66 | 19.67 | 10.52 | 1.18 | 17.35 |
PBDTM(%) | 23.42 | 18.04 | 9 | 0.35 | 16.38 |
PATM(%) | 15.17 | 10.61 | 1.71 | -8.09 | 6.83 |
The launch aligns with Lupin’s strategic push into injectables, biosimilars, and inhalation therapies, supported by robust R&D and manufacturing capabilities
Here are some of the stocks that may see significant price movement today: Bharti Airtel, Torrent Power, Lupin Limited, etc.
This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated in India.
Here are some of the stocks that may see significant price movement today: Godrej Properties, SBI Cards, Hyudai India, etc.
The tablets will be made at the company’s Goa facility, a site that has previously cleared global regulatory inspections and supports Lupin’s key exports.
The company said this deal fits into its larger strategy of expanding respiratory therapies beyond its home markets.
StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin America.
Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.
The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.
The clearance is on the back of a four-day USFDA inspection between June 10 and June 13, 2024.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
